Gresele Paolo, Migliacci Rino, Procacci Alessandra, De Monte Paola, Bonizzoni Erminio
Department of Internal Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Via Enrico dal Pozzo, I-06126 Perugia, Italy.
Thromb Haemost. 2007 Mar;97(3):444-50.
Ischemia/reperfusion damage evokes systemic inflammation and endothelial dysfunction in patients with intermittent claudication. We compared the effects of aspirin with those of a nitric oxide-donating aspirin in preventing the acute, systemic endothelial dysfunction provoked by exercise-induced ischemia of the lower limbs in patients with intermittent claudication. In a prospective, randomized, single-blind, parallel-groups trial among 44 patients with intermittent claudication we compared four weeks of aspirin (100 mg o.d.) with NCX 4016 (800 mg b.i.d.). Primary end point was the exercise-induced changes in brachial flow-mediated vasodilation (FMD) at day 28; secondary end points were effort-induced changes of markers of neutrophil (plasma elastase) and endothelial (soluble VCAM-1) activation. Baseline FMD was comparable in the two groups, both on day 1 (pre-treatment: aspirin = 3.1 +/- 0.5%, nitroaspirin = 3.9 +/- 0.7%, p = NS), and on day 28 (aspirin = 3.4 +/- 0.7%, NCX 4016 = 3.2 +/- 0.6%, p = NS). Maximal treadmill exercise induced an acute worsening of FMD in both groups at baseline (aspirin = -1.15%, nitroaspirin = -1.76%); after four weeks treatment, the impairment of FMD induced by exercise was still present in the aspirintreated group (-1.46%) while it was abolished in the NCX 4016-treated group (+0.79%, p = 0.038 vs. aspirin). Similarly, exercise induced an increase of plasma elastase and of sVCAM-1 which were not affected by aspirin while they were suppressed by NCX 4016. Maximal treadmill exercise induces a systemic arterial endothelial dysfunction in patients with intermittent claudication. A nitric oxide-donating aspirin, but not aspirin, prevents effort-induced endothelial dysfunction.
缺血/再灌注损伤会引发间歇性跛行患者的全身炎症和内皮功能障碍。我们比较了阿司匹林与一氧化氮供体型阿司匹林在预防间歇性跛行患者因运动诱发下肢缺血所引发的急性全身性内皮功能障碍方面的效果。在一项针对44例间歇性跛行患者的前瞻性、随机、单盲、平行组试验中,我们比较了服用四周阿司匹林(每日100毫克)与NCX 4016(每日两次,每次800毫克)的效果。主要终点是第28天时运动诱发的肱动脉血流介导的血管舒张(FMD)变化;次要终点是运动诱发的中性粒细胞(血浆弹性蛋白酶)和内皮(可溶性血管细胞黏附分子-1)激活标志物的变化。两组的基线FMD在第1天(治疗前:阿司匹林=3.1±0.5%,硝基阿司匹林=3.9±0.7%,p=无显著性差异)和第28天(阿司匹林=3.4±0.7%,NCX 4016=3.2±0.6%,p=无显著性差异)时相当。最大运动平板试验在基线时使两组的FMD均急性恶化(阿司匹林=-1.15%,硝基阿司匹林=-1.76%);经过四周治疗后,阿司匹林治疗组中运动诱发的FMD损害仍然存在(-1.46%),而在NCX 4016治疗组中则被消除(+0.79%,与阿司匹林相比p=0.038)。同样,运动使血浆弹性蛋白酶和sVCAM-1增加,阿司匹林对此无影响,而NCX 4016可抑制它们。最大运动平板试验会诱发间歇性跛行患者的全身性动脉内皮功能障碍。一氧化氮供体型阿司匹林而非阿司匹林可预防运动诱发的内皮功能障碍。